First-in-Human trial launches 'Double-Target' cell therapy for tough lymphomas
NCT ID NCT06026319
Summary
This is a first-in-human study testing a new type of personalized cell therapy called CD79b-19 CAR T cells for adults with Non-Hodgkin Lymphoma that has come back or not responded to prior treatments. The main goal is to find a safe dose of these modified immune cells, which are designed to attack cancer by targeting two proteins (CD79b and CD19) on lymphoma cells. Participants will receive one infusion and be followed for up to two years to monitor safety and see if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.